Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Zevra Therapeutics's price to book ratio was 3.2× on Nov 11, 2026, against 3.6× a year earlier. Over the last 5 years it ranged from 1.3× to 14.8×, with a median of 3.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.2× | −0.6 |
| 2025 | Dec 31, 2025 | 3.8× | −2.6 |
| 2024 | Dec 31, 2024 | 6.4× | +2.5 |
| 2023 | Dec 29, 2023 | 3.9× | +2.2 |
| 2022 | Dec 30, 2022 | 1.7× | −0.6 |
| 2021 | Dec 31, 2021 | 2.3× | −160.4 |
| 2016 | Oct 31, 2016 | 162.7× | +95.6 |
| 2015 | Oct 30, 2015 | 67.2× | – |
See a number that looks wrong?